Molnupiravir Dosing with Renal Impairment
Molnupiravir does not require dose adjustment regardless of GFR level, including in patients with severe renal impairment.
Standard Dosing Across All GFR Levels
Molnupiravir is administered at 800 mg orally twice daily for 5 days for all patients, with no modifications needed based on kidney function 1. This represents a significant practical advantage over nirmatrelvir/ritonavir, which requires dose reduction when eGFR is 30-59 mL/min 2.
Evidence Supporting No Dose Adjustment
The pharmacokinetic profile of molnupiravir remains consistent across renal function levels:
- Severe renal impairment (eGFR 15-29 mL/min): A phase 1 trial demonstrated that the 90% confidence interval for plasma NHC (the active metabolite) area under the curve was <2.0 when comparing participants with severe renal impairment to healthy controls 1
- Peak plasma concentrations (Cmax) and overall drug exposure (AUC) were comparable between those with severe renal impairment and healthy participants 1
- Urinary excretion of NHC was already low in healthy participants, and renal clearance was only numerically lower in those with renal impairment—not clinically significant 1
- All adverse events were mild or moderate and resolved by study completion 1
Clinical Context
This no-adjustment dosing makes molnupiravir particularly feasible for:
- Nursing home populations: Where 29% of residents would require nirmatrelvir/ritonavir dose adjustments, molnupiravir requires none 3
- Patients with advanced kidney disease: Who are at increased risk of severe COVID-19 but often excluded from or require complex dosing with other antivirals 1
- Settings with limited laboratory monitoring: Where obtaining or acting on eGFR values may be challenging
Important Caveat
While molnupiravir doesn't require dose adjustment for renal impairment, WHO guidelines suggest nirmatrelvir/ritonavir as the preferred antiviral when feasible due to greater reduction in hospitalization and safety concerns with molnupiravir 2. However, molnupiravir's renal dosing simplicity makes it a practical alternative when nirmatrelvir/ritonavir is contraindicated or unavailable.